Literature DB >> 31037966

Real-world treatment patterns among patients with unresected stage III non-small-cell lung cancer.

Kellie J Ryan1, Karen E Skinner2, Ancilla W Fernandes1, Rajeshwari S Punekar2, Melissa Pavilack1, Mark S Walker2, Noam A VanderWalde3.   

Abstract

Aim: Little is known about recent treatment patterns among patients with unresected stage III NSCLC in the real world. This retrospective study used medical records from USA community oncology practices to address this knowledge gap. Materials & methods: Eligible patients were stage III NSCLC adults diagnosed between 1 January 2011 and 1 March 2016 without surgical resection. Treatment patterns were assessed across three progression intervals, from stage III diagnosis through third progression.
Results: The most common regimen in interval 1 was platinum doublet chemotherapy + radiation therapy, in interval 2 was chemotherapy only, and in interval 3 was non-platinum chemotherapy monotherapy.
Conclusion: Most patients were treated following national guidelines, but important unmet needs remain.

Entities:  

Keywords:  community oncology; concurrent chemoradiation; real-world; sequential chemoradiation; treatment patterns; unmet need; unresected stage III NSCLC

Year:  2019        PMID: 31037966     DOI: 10.2217/fon-2018-0939

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  7 in total

1.  Expression profile and prognostic values of STAT family members in non-small cell lung cancer.

Authors:  Mengqi Yang; Huanting Chen; Lin Zhou; Kai Chen; Fengxi Su
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

2.  Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer.

Authors:  Matthew D Pichert; Maureen E Canavan; Richard C Maduka; Andrew X Li; Theresa Ermer; Peter L Zhan; Michael Kaminski; Brooks V Udelsman; Justin D Blasberg; Henry S Park; Sarah B Goldberg; Daniel J Boffa
Journal:  JAMA Netw Open       Date:  2022-08-01

Review 3.  Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?

Authors:  Jordi Remon; Antonin Levy; Pawan Singh; Lizza E L Hendriks; Mihaela Aldea; Oscar Arrieta
Journal:  Ther Adv Med Oncol       Date:  2022-07-26       Impact factor: 5.485

4.  Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients with locally advanced, unresectable, stage Ⅲ nsclc in china.

Authors:  Xiaotong Jiang; Jinyu Chen; Min Zheng; Hanxue Jia
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

5.  Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience.

Authors:  Milada Zemanova; Robert Pirker; Lubos Petruzelka; Zuzana Zbozínkova; Dragana Jovanovic; Mirjana Rajer; Krisztina Bogos; Gunta Purkalne; Vesna Ceriman; Subhash Chaudhary; Igor Richter; Jirí Kufa; Lenka Jakubikova; Marius Zemaitis; Marketa Cernovska; Leona Koubkova; Zdenka Vilasova; Karin Dieckmann; Attila Farkas; Jelena Spasic; Katerina Fröhlich; Andreas Tiefenbacher; Virag Hollosi; Juraj Kultan; Iveta Kolarová; Jiri Votruba
Journal:  Radiol Oncol       Date:  2020-05-28       Impact factor: 2.991

Review 6.  Targeted therapies for unresectable stage III non-small cell lung cancer.

Authors:  Jordi Remon; Lizza E L Hendriks
Journal:  Mediastinum       Date:  2021-09-25

7.  Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population.

Authors:  Ho Cheol Kim; Wonjun Ji; Jae Cheol Lee; Hyeong Ryul Kim; Si Yeol Song; Chang-Min Choi
Journal:  Cancer Res Treat       Date:  2021-02-16       Impact factor: 4.679

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.